PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina
Completed
Cytokinetics
Phase 2
This study investigates whether symptom-limited exercise capacity in ischemic cardiomyopathy
patients with angina is deleteriously affected by treatment with CK-1827452.
Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients
Withdrawn
Amgen
Phase 2
The purpose of this trial is to obtain a pharmacokinetic profile (i.e. amount of drug in the
blood over time) of Omecamtiv mecarbil in patients with stable heart failure.
Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients
Withdrawn
Cytokinetics
Phase 2
The purpose of this trial is to obtain a pharmacokinetic profile (i.e. amount of drug in the
blood over time) of Omecamtiv mecarbil in patients with stable heart failure.
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
Completed
Cytokinetics
Phase 2
The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV)
omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular
systolic dysfunction hospitalized for acute heart failure. This is a multicenter, randomized,
double-blind, placebo-controlled study with 3 dose cohorts enrolled sequentially in order of
ascending dose strength of omecamtiv mecarbil. In each cohort, subjects are randomized 1:1 to
omecamtiv mecarbil or placebo.
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
Completed
Amgen
Phase 2
The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV)
omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular
systolic dysfunction hospitalized for acute heart failure. This is a multicenter, randomized,
double-blind, placebo-controlled study with 3 dose cohorts enrolled sequentially in order of
ascending dose strength of omecamtiv mecarbil. In each cohort, subjects are randomized 1:1 to
omecamtiv mecarbil or placebo.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
